NEW YORK, March 24 Reportlinker.com announces that a new market research report is available in its catalogue:
Osteoporosis - Drug Pipeline Analysis and Market Forecasts to 2016
Advertisement
http://www.reportlinker.com/p0183457/Osteoporosis---Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016.html
Osteoporosis - Drug Pipeline Analysis and Market Forecasts to 2016
Advertisement
Summary
GlobalData, the industry analysis specialist's new report, "Osteoporosis - Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global osteoporosis market. The report identifies the key trends shaping and driving the global osteoporosis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global osteoporosis sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.
Scope
The scope of the report includes:
- Annualized global osteoporosis market revenues data from 2001 to 2009, forecast forward for 7 years to 2016.
- Geographic markets covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
- Analysis of the current and future market competition in the global osteoporosis market. Key players covered include Amgen, Merck & Pfizer.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future market associated with osteoporosis.
Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global osteoporosis market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global osteoporosis market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global osteoporosis market landscape? - Identify, understand and capitalize.
Companies Mentioned
Amgen
Merck
Pfizer
Table of Contents
1 Table of contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Osteoporosis Market: Market Characterization 6
2.1 Overview 6
2.2 Osteoporosis Therapeutics Market Size 6
2.3 Osteoporosis Therapeutics Market Forecast and CAGR 7
2.4 Drivers and Barriers for the Osteoporosis Therapeutics Market 8
2.4.1 Drivers for the Osteoporosis Therapeutics Market 8
2.4.2 Barriers for the Osteoporosis Therapeutics Market 9
2.5 Opportunity and Unmet Need 9
2.6 Key Takeaway 10
3 Osteoporosis Therapeutics Market: Competitive Assessment 11
3.1 Overview 11
3.2 Strategic Competitor Assessment 11
3.3 Product Profile for the Major Marketed Products in the Osteoporosis Therapeutics Market 12
3.3.1 Fosamax (alendronate sodium) 12
3.3.2 Actonel (risedronate sodium) 13
3.3.3 Evista (raloxifene hydrochloride) 15
3.3.4 Boniva (ibandronate sodium) 17
3.3.5 Forteo (teriparatide [rDNA origin]) injection 18
3.4 Key Takeaway 20
4 Osteoporosis Therapeutics Market: Pipeline Assessment 21
4.1 Overview 21
4.2 Strategic Pipeline Assessment 21
4.2.1 Technology Trends Analytic Framework 21
4.3 Osteoporosis Therapeutics - Promising Drugs under Clinical Development 22
4.4 Molecule Profile for Promising Drugs under Clinical Development 22
4.4.1 Prolia (denosumab) 22
4.4.2 MK-0822 (odanacatib) 23
4.4.3 Viviant (bazedoxifene) 24
4.4.4 PREOS (parathyroid hormone 1-84 [rDNA origin] injection) 24
4.5 Osteoporosis Therapeutics Market - Clinical Pipeline by Mechanism of Action 25
4.6 Osteoporosis Therapeutics Pipeline - Pipeline by Clinical Phases of Development 26
4.6.1 Osteoporosis Therapeutics - Phase III Clinical Pipeline 26
4.6.2 Osteoporosis Therapeutics - Phase II Clinical Pipeline 28
4.6.3 Osteoporosis Therapeutics - Phase I Clinical Pipeline 30
4.6.4 Osteoporosis Therapeutics - Pre-clinical Pipeline 31
4.6.5 Osteoporosis Therapeutics - Discovery Pipeline 31
4.7 Key Takeaway 32
5 Osteoporosis Therapeutics Market: Implications for Future Market Competition 33
6 Osteoporosis Therapeutics Market: Future Players in the Osteoporosis Therapeutics Market 34
6.1 Introduction 34
6.2 Amgen 34
6.2.1 Overview 34
6.2.2 Osteoporosis Portfolio 34
6.2.3 Osteoporosis Pipeline Portfolio 35
6.3 Merck 35
6.3.1 Overview 35
6.3.2 Osteoporosis Portfolio 36
6.3.3 Osteoporosis Pipeline Portfolio 36
6.4 Pfizer 36
6.4.1 Overview 36
6.4.2 Osteoporosis Portfolio 37
6.4.3 Osteoporosis Pipeline Portfolio 37
7 Osteoporosis Therapeutics Market: Appendix 38
7.1 Definitions 38
7.2 Acronyms 38
7.3 Research Methodology 39
7.3.1 Coverage 40
7.3.2 Secondary Research 40
7.3.3 Forecasting 40
7.3.4 Primary Research 42
7.3.5 Expert Panel Validation 43
7.4 Contact Us 43
7.5 Disclaimer 43
7.6 Sources 43
List of Tables
1.1 List of Tables
Table 1: Osteoporosis Therapeutics Market, Global, Revenues ($bn), 2001-2009 7
Table 2: Osteoporosis Therapeutics Market, Global, Revenue Forecasts ($bn), 2009-2016 8
Table 3: Drugs Approved by FDA to Prevent and/or Treat Osteoporosis 11
Table 4: Effect of Actonel 5mg on the Risk of Vertebral Fractures 15
Table 5: Mean Percent Increase in BMD from Baseline in Patients Taking Actonel 5mg 15
Table 6: Effect of Evista on Risk of Vertebral Fractures 16
Table 7: Evista - (60mg Once Daily) Related Increases in BMD for the Osteoporosis Treatment vs. Placebo 17
Table 8: Effect of Forteo on Risk of Vertebral Fractures in Postmenopausal Women with Osteoporosis 19
Table 9: Mean Percent Change in BMD in Postmenopausal Women with Osteoporosis 19
Table 10: Major Marketed Products Comparison in the Osteoporosis Therapeutics Market, 2010 20
Table 11: Osteoporosis Therapeutics - Most Promising Drugs Under Clinical Development, 2010 22
Table 12: Osteoporosis Therapeutics - Phase III Clinical Pipeline, 2010 26
Table 13: Osteoporosis Therapeutics - Phase II Clinical Pipeline, 2010 28
Table 14: Osteoporosis Therapeutics - Phase I Clinical Pipeline, 2010 30
Table 15: Osteoporosis Therapeutics - Pre-Clinical Pipeline, 2010 31
Table 16: Osteoporosis Therapeutics - Discovery Pipeline, 2010 31
Table 17: Amgen - Osteoporosis Pipeline Products, 2010 34
Table 18: Merck - Osteoporosis Pipeline Products, 2010 36
Table 19: Pfizer - Osteoporosis Pipeline Products, 2010 37
List of Figures
1.2 List of Figures
Figure 1: Osteoporosis Therapeutics Market, Global, Revenues ($bn), 2001-2009 7
Figure 2: Osteoporosis Therapeutics Market, Global, Revenue Forecasts ($bn), 2009-2016 8
Figure 3: Opportunity and Unmet Need in the Osteoporosis Therapeutics Market, 2010 10
Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Osteoporosis Therapeutics, 2010 12
Figure 5: Technology Trends Analytic Framework of the Osteoporosis Pipeline, 2010 21
Figure 6: Technology Trends Analytic Framework of the Osteoporosis Therapeutics Pipeline - Description, 2010 22
Figure 7: Osteoporosis Therapeutics Market, Global, Clinical Pipeline by Mechanism of Action (%), 2010 25
Figure 8: Osteoporosis Therapeutics Pipeline by Phase of Clinical Development, 2010 26
Figure 9: Implications for Future Market Competition in the Osteoporosis Therapeutics Market, 2010 33
Figure 10: Osteoporosis Therapeutics Market - Clinical Pipeline by Company (No. of Molecules), 2010 34
Figure 11: GlobalData Methodology 39
Figure 12: GlobalData Market Forecasting Model 42
To order this report:
Medical Devices Industry: Osteoporosis - Drug Pipeline Analysis and Market Forecasts to 2016
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Contact Nicolas Bombourg Reportlinker Email: [email protected] US: (805)652-2626 Intl: +1 805-652-2626
SOURCE Reportlinker
